At a glance
Sothema makes and sells medicines in Morocco and abroad, notably in oncology, cardiology and diabetes. The group has a subsidiary in Senegal.
History
Sothema was founded in 1976 and listed in 2005, selling 15% of its capital. In 2021 it ran the clinical trials of the Sinopharm vaccine in Morocco, and its sterile filling units were chosen for local production.
Latest published results
In the first half of 2026, consolidated revenue rose 16% to MAD 1.8 billion. EBITDA increased 12% to MAD 394 million and net income attributable to the group 11% to MAD 215 million. Net debt fell to MAD 681 million. The company obtained 37 marketing authorisations.
What to watch
Expansion in Africa and the Middle East and new product launches.
Key dates
- 1976
Company founded.
- 2005
IPO, with 15% of the capital sold.
- 2021
Moroccan-Chinese agreement in July to produce the Sinopharm vaccine, using Sothema's filling units.
- 2026
Purchase of the CIALIS brand rights from Lilly and a five-for-one split of the share's nominal value.
Sources: Boursenews, Sothema : résultats du premier semestre 2026, September 29, 2026; African Markets, fiche société Sothema, October 29, 2026; Boursenews, Bourse : Sothema dans la cour des grands, August 16, 2021.
Profile updated on October 29, 2026.